Trial Profile

An Open-label, Single-arm, Multicenter, Phase II Clinical Study of the Efficacy and Safety of Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Patients With Untreated Advanced Pancreatic Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Serplulimab (Primary)
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Therapeutic Use

01 Jun 2025 According to a Shanghai Henlius Biotech media release, data from this study presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
20 Dec 2024 According to a Henlius Biopharmaceuticals Media Release, data from this study were presented at the APA/JPS/CAP/IAP 2024 Annual Meeting.
20 Dec 2024 Results presented in a Henlius Biopharmaceuticals Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com